Orchestra BioMed Holdings Cash Flow Statement Analysis

Operating, investing, and financing activities in millions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for Orchestra BioMed Holdings, Inc. (OBIO) - Annual data in millions USD
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Operating Activities
Net Income-61.02-49.12-33.61-23.01-21.36
Depreciation & Amortization0.310.290.220.180.14
Stock Based Compensation10.627.633.410.300.22
Change in Working Capital-0.77-3.31-0.452.60-8.19
Change in Accounts Receivable0.020.000.030.05-0.08
Change in Inventory-0.030.13-0.210.00-0.03
Change in Accounts Payable2.970.153.351.08-2.61
Change in Other Working Capital0.24-3.080.130.22-0.31
Other Operating Activities0.24-3.080.130.220.07
Net Cash from Operating Activities-50.56-46.13-29.29-19.43-26.18
Investing Activities
Capital Expenditures-0.29-0.08-0.59-0.27-0.54
Acquisitions-0.600.000.000.000.00
Purchases of Investments-72.65-142.03-63.53-0.2127.69
Sales/Maturities of Investments86.63152.800.0013.500.00
Other Investing Activities0.000.000.00-0.21-0.19
Net Cash from Investing Activities13.0910.69-64.1213.0226.97
Financing Activities
Debt Repayment15.00-10.85-6.45-4.000.00
Common Stock Issued15.040.25109.830.010.00
Other Financing Activities-1.1056.81-10.320.000.00
Net Cash from Financing Activities29.1746.22103.26-3.9910.00
Summary
Net Change in Cash-8.3010.789.85-10.4110.78
Cash at Beginning of Period30.5619.789.9420.340.00
Cash at End of Period22.2630.5619.789.940.00
Free Cash Flow-50.85-46.21-29.88-19.70-26.72
Supplemental Disclosures
Interest Paid0.101.121.370.390.00